We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,073

Opportunities for Increased Drug Sales to the VA
  • Foley & Lardner LLP
  • USA
  • May 25 2016

Pharmaceutical manufacturers that produce drugs in non-designated countries under the Trade Agreements Act (TAA) may now have an opportunity to


Health Care Employees at the Frontline in The Battle Against Ransomware
  • Foley & Lardner LLP
  • USA
  • May 25 2016

As recent noteworthy attacks have shown, no health care organization or provider is safe from ransomware threats, and the results of an attack can be


CAFC Affirms Finacea Gel Infringement Under Doctrine Of Equivalents
  • Foley & Lardner LLP
  • USA
  • May 24 2016

In Intendis GmbH v. Glenmark Pharmaceuticals Inc., USA, the Federal Circuit affirmed the district court decision that found infringement under the


New EEOC Rules for Wellness Programs: A 30 Percent Incentive Voluntary
  • Foley & Lardner LLP
  • USA
  • May 23 2016

For years, employers have been allowed to offer voluntary wellness programs to employees under the Genetic Information Nondiscrimination Act (GINA


Despite Barriers, Community Speciality Clinics are Eager to Adopt Precision Medicine Tools
  • Foley & Lardner LLP
  • USA
  • May 22 2016

Fueled by technological advances, scientific breakthroughs and significant financial investments, precision medicine (PM) has emerged as a promising


USPTO 101 Guidance: Microneedles Versus Prosthetic Devices
  • Foley & Lardner LLP
  • USA
  • May 19 2016

When I first wrote about the new natural products Subject Matter Eligibility Examples issued by the USPTO on May 4, 2016, I noted a puzzling


Finance Committee Report Place Medical Device Arrangements under Increasing Scrutiny
  • Foley & Lardner LLP
  • USA
  • May 18 2016

Hospitals and providers participating in physician-owned distributorships, or "PODs" may be at increased risk for government investigation or


Amgen And Sandoz Do The Biosimilar Patent Dance Over Neulasta
  • Foley & Lardner LLP
  • USA
  • May 17 2016

Amgen Inc. has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by


House of Representatives v. Burwell: Another Blow to Obamacare
  • Foley & Lardner LLP
  • USA
  • May 16 2016

Federal Judge Rosemary Collyer's May 12, 2016 ruling in House of Representatives v. Burwell, found that the Obama administration (the


FDA Outlines Future Medical Device Coordinating Center
  • Foley & Lardner LLP
  • USA
  • May 11 2016

The federal Food and Drug Administration’s planning board (Planning Board) for a medical device evaluation system (NMDES) recently recommended the